Pulmonology

Two doses of the Pfizer COVID-19 vaccine also showed sustained efficacy of 93% against Delta-related hospital admission.

Janssen's investigational vaccine showed efficacy of up to 80% in preventing RSV-mediated lower respiratory tract infections in older adults.

COVID-19 case increases in the past 7 days range from 100% to 3.16% among the 10 states with the most significant rises. Is your state among these?

A variety of exposures in the work environment can cause asthma in some employees, according to new research presented at ERS Virtual International Congress 2021.

The albuterol/budesonide combination significantly reduced the risk of severe exacerbations and improved lung function in mild-to-moderate asthma.

Ivermectin has shown no clinical benefit for the many viral infections it has been studied in - including COVID-19. Why are patients buying it and physicians prescribing it?

Schaffner, medical director of the National Foundation for Infectious Disease, says we need to re-educate on the dangers of flu and "sell" the influenza vaccine to the vaccine-fatigued.

A new study found several risk factors associated with severe adult-onset asthma, including smoking, NSAID-exacerbated respiratory disease, and sibling count.

FDA approval of mezopelumab follows the phase 3 SYNAPSE trial in which the anti-Il-5 monoclonal antibody reduced by 57% the need for nasal polyp surgery.

Tezepelumab, a novel human monoclonal antibody that shows promise to reduce exacerbations across asthma phenotypes, was granted FDA Priority Review.

A new study found public health measures designed to curb COVID-19 transmissions may have fostered a significant side benefit: reduced COPD hospital admissions.

Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.

For patients with moderate-to-severe persistent asthma, new guidelines from the NAEPP recommend SMART, particularly for patients with a recent disease exacerbation.

ATS 2021: In a subgroup of oral corticosteroid-dependent patients with severe asthma from the newly released NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function.

ATS.2021. Study authors categorized asthma patients using age at onset, T2 biomarkers, and IL-6 levels, creating 12 phenotypes for additional study.

ATS 2021: The risk of morbidity and death in patients with COPD increases among those with moderate exacerbation, and even more so for severe exacerbation, new research suggests.

In an abstract being presenting at the upcoming ATS 2021 International Conference, researchers estimate that by 2050 the US will lead the Americas in prevalence of COPD.

American Thoracic Society 2021 International Conference: In a subset of patients from the ETHOS study, triple combination therapy was found beneficial for those with moderate COPD.

New findings suggest that patients with asthma and type 2 diabetes who use GLP-1 RAs for diabetes treatment intensification have fewer asthma exacerbations compared to other diabetes drugs.

Patients with asthma or COPD living in areas with high levels of air pollution are at an increased risk of hospitalization if they contract COVID-19, suggests a new pilot study.

Long COVID is now a term recognized worldwide. We talked with Ani Nalbandian, MD, lead author of the most comprehensive review-to-date, about what she and her colleagues have learned.

Individuals vaccinated against influenza were 24% less likely to be infected with COVID-19 than those who did not get the flu shot, according to Michigan Medicine researchers.

Asthma of obesity affects more than 10% of men and 14% of women with obesity. Our interview with researcher Anne Dixon, MD, sheds light on this poorly appreciated asthma phenotype.

Research into biologic therapy for asthma and COPD has been both successful and frustrating. Find out what you know about the progress with these 8 questions.